Business Description
Racura Oncology Ltd
ISIN : AU000000RAC3
Description
Racura Oncology Ltd is a Phase 3 clinical-stage biopharmaceutical company with a dedicated mission to silence cancer. The company's clinical programs include the Phase 3 EMILI trial in acute myeloid leukaemia, the Phase 1a/b HARNESS trial in combination with osimertinib for EGFR-mutated non-small cell lung cancer, and the Phase 1a/b CPACS trial in combination with doxorubicin, where it aims to deliver both anthracycline cardioprotection and enhanced anticancer activity. The company operated in two segments, being research into an oncology drug, RC220, and the manufacturing and distribution of the drug for clinical trials.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.96 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4.2 | |||||
3-Year FCF Growth Rate | 11.3 | |||||
3-Year Book Growth Rate | 6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.26 | |||||
9-Day RSI | 61.58 | |||||
14-Day RSI | 57.29 | |||||
3-1 Month Momentum % | -24.84 | |||||
6-1 Month Momentum % | -19.87 | |||||
12-1 Month Momentum % | 89.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.43 | |||||
Quick Ratio | 21.43 | |||||
Cash Ratio | 21.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.3 | |||||
Shareholder Yield % | -6.85 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -43.75 | |||||
ROA % | -41.4 | |||||
ROIC % | -395.8 | |||||
3-Year ROIIC % | -85.98 | |||||
ROC (Joel Greenblatt) % | -334350 | |||||
ROCE % | -52.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 11.56 | |||||
Price-to-Tangible-Book | 12.9 | |||||
EV-to-EBIT | -28.96 | |||||
EV-to-EBITDA | -29.58 | |||||
EV-to-FCF | -46.96 | |||||
| Price-to-Net-Current-Asset-Value | 12.9 | |||||
| Price-to-Net-Cash | 12.9 | |||||
Earnings Yield (Greenblatt) % | -3.45 | |||||
FCF Yield % | -1.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Racura Oncology Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.037 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 111.83 | ||
| 14-Day RSI | 57.29 | ||
| 14-Day ATR (€) | 0.031639 | ||
| 20-Day SMA (€) | 1.211 | ||
| 12-1 Month Momentum % | 89.06 | ||
| 52-Week Range (€) | 0.64 - 2.64 | ||
| Shares Outstanding (Mil) | 196.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Racura Oncology Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Racura Oncology Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Racura Oncology Ltd Frequently Asked Questions
What is Racura Oncology Ltd(FRA:FN3)'s stock price today?
The current price of FRA:FN3 is €1.29. The 52 week high of FRA:FN3 is €2.64 and 52 week low is €0.64.
When is next earnings date of Racura Oncology Ltd(FRA:FN3)?
The next earnings date of Racura Oncology Ltd(FRA:FN3) is .
Does Racura Oncology Ltd(FRA:FN3) pay dividends? If so, how much?
Racura Oncology Ltd(FRA:FN3) does not pay dividend.
Press Release
Articles on Racura Oncology Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers